science-innovation/
124 pages · Updated August 3, 2026
Pages
- Pardon Our Interruption
- Early Access Treatments & Compassionate Use Programs | Boehringer Ingelheim
- Pardon Our Interruption
- Vicadrostat (BI 690517) / empagliflozin | Boehringer Ingelheim
- Eye Health | Boehringer Ingelheim
- BI 764524: Sema3A antibody | Boehringer Ingelheim
- Vicadrostat (BI 690517) / empagliflozin | Boehringer Ingelheim
- Vicadrostat (BI 690517) / empagliflozin | Boehringer Ingelheim
- BI 3032950: TREM-1 antagonist | Boehringer Ingelheim
- Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | Boehringer Ingelheim
- BI 771716: Antibody fragment | Boehringer Ingelheim
- BI 1584862: Phospholipid modulator | Boehringer Ingelheim
- Pardon Our Interruption
- Vicadrostat (BI 690517) / empagliflozin | Boehringer Ingelheim
- BI 1815368: Oral vascular modulator | Boehringer Ingelheim
- BI 3000202: Immunomodulator | Boehringer Ingelheim
- Nerandomilast (BI 1015550): PDE4B inhibitor | Boehringer Ingelheim
- Tenecteplase: Fibrinolytic | Boehringer Ingelheim
- Pardon Our Interruption
- Survodutide (BI 456906): GCGR/GLP1 agonist | Boehringer Ingelheim
- Oncology | Boehringer Ingelheim
- Apecotrep (BI 764198): TRPC6 inhibitor | Boehringer Ingelheim
- Nerandomilast (BI 1015550): PDE4B inhibitor | Boehringer Ingelheim
- Survodutide (BI 456906): GCGR/GLP1 agonist | Boehringer Ingelheim
- Nerandomilast (BI 1015550): PDE4B inhibitor | Boehringer Ingelheim
- Mental Health | Boehringer Ingelheim
- Verducatib (BI 1291583): DPP1/CatC Inhibitor | Boehringer Ingelheim
- Apecotrep (BI 764198): TRPC6 inhibitor | Boehringer Ingelheim
- Immunology | Boehringer Ingelheim
- Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | Boehringer Ingelheim
- Heidelberg Transforming Science Day 2025 | Boehringer Ingelheim
- SIRPα antagonist | Boehringer Ingelheim
- Ezabenlimab: PD-1 antibody | Boehringer Ingelheim
- Second generation STING agonist | Boehringer Ingelheim
- B7-H6/CD3 T-Cell Engager | Boehringer Ingelheim
- CD137/FAP agonist | Boehringer Ingelheim
- Anti-inflammatory agent | Boehringer Ingelheim
- Anti-fibrotic agent | Boehringer Ingelheim
- Obrixtamig: DLL3/CD3 T-cell engager | Boehringer Ingelheim
- Immunological fusion protein | Boehringer Ingelheim
- Acyltransferase inhibitor | Boehringer Ingelheim
- Modified yersinia | Boehringer Ingelheim
- Obrixtamig (BI 764532): DLL3/CD3 T-cell engager | Boehringer Ingelheim
- Glutamate receptor modulator | Boehringer Ingelheim
- Receptor agonist | Boehringer Ingelheim
- PD-1 antibody | Boehringer Ingelheim
- T-cell engager | Boehringer Ingelheim
- Anti-fibrotic agent | Boehringer Ingelheim
- Glutamate receptor modulator | Boehringer Ingelheim
- Targeted cancer immunotherapy | Boehringer Ingelheim
- Immunomodulator | Boehringer Ingelheim
- Immunomodulator | Boehringer Ingelheim
- Anti-fibrotic agent | Boehringer Ingelheim
- Triple agonist peptide | Boehringer Ingelheim
- Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | Boehringer Ingelheim
- Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | Boehringer Ingelheim
- IL-11 antibody (BI 765423) | Boehringer Ingelheim
- Lysophospholipase inhibitor (BI 1819479) | Boehringer Ingelheim
- Animal Health Innovation | Boehringer Ingelheim
- Human Health Innovation | Boehringer Ingelheim
- Science Stories | Boehringer Ingelheim
- Science Focus | Boehringer Ingelheim
- Fostering Science | Boehringer Ingelheim
- Science & Innovation | Boehringer Ingelheim
- Grass Roots | Boehringer Ingelheim
- Vaccines | Boehringer Ingelheim
- Parasiticides | Boehringer Ingelheim
- Therapeutics | Boehringer Ingelheim
- VSV-GP | Boehringer Ingelheim
- Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | Boehringer Ingelheim
- Zongertinib: HER2 Tyrosine Kinase Inhibitor (TKI) | Boehringer Ingelheim
- Obrixtamig (BI 764532): DLL3/CD3 T-cell engager | Boehringer Ingelheim
- Human Pharma Clinical Pipeline | Boehringer Ingelheim
- Clinical Studies | Boehringer Ingelheim
- The Research Process | Boehringer Ingelheim
- Human health therapeutic strategies and modalities toolbox | Boehringer Ingelheim
- Boehringer licenses Immunitas‘ novel antibody program | Boehringer Ingelheim
- Research Beyond Borders | Boehringer Ingelheim
- Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Boehringer Ingelheim
- Boehringer-BioNTech partnership to advance SCLC therapy | Boehringer Ingelheim
- Ecuador Accelerates Efforts to Eliminate Dog‑Mediated Rabies | Boehringer Ingelheim
- Where ideas take root: Get a glimpse into our Grass Roots efforts | Boehringer Ingelheim
- Networking opportunities for biotech startups and innovators | Boehringer Ingelheim
- Boehringer Ingelheim’s Global Research Sites | Boehringer Ingelheim
- Addressing unmet inflammatory bowel disease needs | Boehringer Ingelheim
- New trial explores advancements in IPF treatment | Boehringer Ingelheim
- Boehringer advances obesity treatment to mid-stage development | Boehringer Ingelheim
- Empowering future veterinarians, serving the community | Boehringer Ingelheim
- Oncolytic viruses: From the lab to the clinic | Boehringer Ingelheim
- Computational Innovation | Boehringer Ingelheim
- Phase II start of oral treatment for diabetic macular edema | Boehringer Ingelheim
- Opening doors with open science | Boehringer Ingelheim
- Phase II start of oral treatment for Geographic Atrophy | Boehringer Ingelheim
- Researchers from industry and academic background come together. | Boehringer Ingelheim
- New collaboration to develop treatment for autoimmune diseases | Boehringer Ingelheim
- Research in cardiovascular, renal, and metabolic diseases | Boehringer Ingelheim
- SEMINTRA 4mg/ml oral solution cats chronic kidney disease hypertension | Boehringer Ingelheim
- Unlocking the ‘dark genome’ for cancer immunotherapy | Boehringer Ingelheim
- Collaboration with Mary Tyler Moore Vision Initiative | Boehringer Ingelheim
- Future Leaders in Veterinary Medicine and Research | Boehringer Ingelheim
- vaccine protection leptospirosis in dogs | Boehringer Ingelheim
- New cancer research building: Boosting innovation in oncology | Boehringer Ingelheim
- Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio | Boehringer Ingelheim
- Positive results Diabetic Macular Ischemia treatment | Boehringer Ingelheim
- Patient centricity and site centricity in clinical trials | Boehringer Ingelheim
- All eyes on vision loss | Boehringer Ingelheim
- “My ultimate goal is to cure cancer” | Boehringer Ingelheim
- New study paves the way for liver cirrhosis treatments | Boehringer Ingelheim
- Boehringer Ingelheim Venture Fund invests precision antimicrobials | Boehringer Ingelheim
- Targeting HER2 in cancer: The story of zongertinib | Boehringer Ingelheim
- Making sustainable medicines through eco-design | Boehringer Ingelheim
- Partnership with Precision Health Research, Singapore | Boehringer Ingelheim
- Our Innovation Strategy | Boehringer Ingelheim
- T-cell engagers: Reawakening T-cells to fight cancer | Boehringer Ingelheim
- The Boehringer Ingelheim Veterinary Scholars Program | Boehringer Ingelheim
- Joint venture to fight Antimicrobial Resistance | Boehringer Ingelheim
- Biotherapeutics Discovery | Boehringer Ingelheim
- Collaboration-with-OxfordBioTherapeutics | Boehringer Ingelheim
- Eye Health Research | Boehringer Ingelheim
- Access to Healthcare Strategy Innovation | Boehringer Ingelheim
- Open Innovation at Boehringer Ingelheim | Boehringer Ingelheim
- Cancer research | Boehringer Ingelheim
- Immunology Respiratory Research | Boehringer Ingelheim
- Central Nervous System Diseases | Boehringer Ingelheim